# Pharvaris (stock symbol: PHVS) Logo in transparent PNG and SVG formats

## Pharvaris Logo large

### Pharvaris Logo large Download PNG (29.77 KB)

![Pharvaris Logo large Download PNG (29.77 KB)](/img/orig/PHVS_BIG-6bf4d656.png)

### Pharvaris Logo large Download SVG (3.88 KB)

![Pharvaris Logo large Download SVG (3.88 KB)](/img/orig/PHVS_BIG-9d1ac7f1.svg)

## Pharvaris Logo icon format

### Pharvaris Logo icon format Download PNG (16.97 KB)

![Pharvaris Logo icon format Download PNG (16.97 KB)](/img/orig/PHVS-f861375e.png)

### Pharvaris Logo icon format Download SVG (677 Bytes)

![Pharvaris Logo icon format Download SVG (677 Bytes)](/img/orig/PHVS-e0a7456f.svg)

## About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

1. Website domain: pharvaris.com
2. Employees: 47
3. Marketcap: $0.31 Billion USD


## Categories
- [x] ðŸ‡³ðŸ‡± Netherland
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
